Corteva, Inc. (CTVA) Spending and interest coverage
- R&D / revenue · 12 months: Value 8.38%; Formula and calculation Research and development expense / revenue. Period ending 2026-06-30..
- Stock-based compensation / revenue · 12 months: Value (m); Formula and calculation Share-based compensation / revenue. Period ending 2026-06-30..
- Interest coverage · 12 months: Value (m); Formula and calculation Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified..
Spending and interest coverage
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| R&D / revenue · 12 months | 8.38% | Research and development expense / revenue. Period ending 2026-06-30. $1.49B ÷ $17.81B × 100 ≈ 8.38% |
| Stock-based compensation / revenue · 12 months | (m) | Share-based compensation / revenue. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Interest coverage · 12 months | (m) | Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Research and development spending | 1.49B USD | Research and Development Expense |
| Revenue | 17.81B USD | |
| Stock-based compensation | (m) | |
| Operating income | (m) | |
| Interest expense · reported / estimated | (m) | · Estimated expense assumptions |
Latest interest expense basis: (m). Estimated values carry *; expand each history row’s basis for its dated balances and rate assumptions.
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Research and development spending (USD) | Revenue (USD) | Stock-based compensation (USD) | Operating income (USD) | Interest expense · reported / estimated (USD) | R&D / revenue | SBC / revenue | Interest coverage | Interest expense basis |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $1.49B | $17.81B | (m) | (m) | (m) | 8.38% | (m) | (m) | (m) |
| 2026-03-31 | $1.48B | $17.89B | (m) | (m) | (m) | 8.27% | (m) | (m) | (m) |
| 2025-12-31 | $1.47B | $17.40B | (m) | (m) | (m) | 8.47% | (m) | (m) | (m) |
| 2025-09-30 | $1.43B | $17.47B | (m) | (m) | (m) | 8.16% | (m) | (m) | (m) |
| 2025-06-30 | $1.42B | $17.18B | (m) | (m) | (m) | 8.28% | (m) | (m) | (m) |
| 2025-03-31 | $1.41B | $16.83B | (m) | (m) | (m) | 8.35% | (m) | (m) | (m) |
| 2024-12-31 | $1.40B | $16.91B | (m) | (m) | (m) | 8.29% | (m) | (m) | (m) |
| 2024-09-30 | $1.39B | $16.64B | (m) | (m) | (m) | 8.38% | (m) | (m) | (m) |
| 2024-06-30 | $1.38B | $16.90B | (m) | (m) | (m) | 8.17% | (m) | (m) | (m) |
| 2024-03-31 | $1.35B | $16.83B | (m) | (m) | (m) | 8.04% | (m) | (m) | (m) |
| 2023-12-31 | $1.34B | $17.23B | (m) | (m) | (m) | 7.76% | (m) | (m) | (m) |
| 2023-09-30 | $1.32B | $17.34B | (m) | (m) | (m) | 7.61% | (m) | (m) | (m) |
| 2023-06-30 | $1.30B | $17.53B | (m) | (m) | (m) | 7.40% | (m) | (m) | (m) |
| 2023-03-31 | $1.26B | $17.74B | (m) | (m) | (m) | 7.13% | (m) | (m) | (m) |
| 2022-12-31 | $1.22B | $17.45B | (m) | (m) | (m) | 6.97% | (m) | (m) | (m) |
| 2022-09-30 | $1.19B | $17.11B | (m) | (m) | (m) | 6.97% | (m) | (m) | (m) |
| 2022-06-30 | $1.18B | $16.70B | (m) | (m) | (m) | 7.05% | (m) | (m) | (m) |
| 2022-03-31 | $1.17B | $16.08B | (m) | (m) | (m) | 7.30% | (m) | (m) | (m) |
| 2021-12-31 | $1.19B | $15.65B | (m) | (m) | (m) | 7.58% | (m) | (m) | (m) |
| 2021-09-30 | $1.18B | $15.38B | (m) | (m) | (m) | 7.64% | (m) | (m) | (m) |
| 2021-06-30 | $1.16B | $14.88B | (m) | (m) | (m) | 7.82% | (m) | (m) | (m) |
| 2021-03-31 | $1.14B | $14.44B | (m) | (m) | (m) | 7.92% | (m) | (m) | (m) |
| 2020-12-31 | $1.14B | $14.22B | (m) | (m) | (m) | 8.03% | (m) | (m) | (m) |
| 2020-09-30 | $1.13B | $13.99B | (m) | (m) | (m) | 8.05% | (m) | (m) | (m) |
| 2020-06-30 | $1.13B | $14.04B | (m) | (m) | (m) | 8.06% | (m) | (m) | (m) |
| 2020-03-31 | $1.13B | $14.41B | (m) | (m) | (m) | 7.83% | (m) | (m) | (m) |
| 2019-12-31 | $1.15B | $13.85B | (m) | (m) | (m) | 8.28% | (m) | (m) | (m) |
| 2019-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2019-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2019-03-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2018-12-31 | $1.35B | $14.29B | (m) | (m) | (m) | 9.48% | (m) | (m) | (m) |
| 2018-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2018-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2018-03-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2017-12-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2017-08-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| DEL MONTE CORP (DMC) | $1.439B | 40.52 | |
| Dole plc (DOLE) | $1.218B | 21.71 | |
| Village Farms International, Inc. (VFF) | $0.382B | 10.68 | |
| ALICO, INC. (ALCO) | United States | $0.289B | 200.08 |
| Limoneira CO (LMNR) | United States | $0.218B | -5.53 |
| Local Bounti Corporation/DE (LOCL) | United States | $0.025B | -0.45 |
| BLOOMIA HOLDINGS, INC. (TULP) | United States | $0.016B | -1.54 |
| Edible Garden AG Inc (EDBL) | United States | $0.002B |